SGLT2 inhibiting compounds are provided having the formulawhereR1, R2, and R2a are independently hydrogen, OH, OR5, lower alkyl, CF3, OCHF2, OCF3, SR5i or halogen, or two of R1, R2 and R2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle；R3 and R4 are independently hydrogen, OH, OR5a, OAryl, OCH2Aryl, lower alkyl, cycloalkyl, CF3, -OCHF2, -OCF3, halogen, -CN, -CO2R5b, -CO2H, -COR6b, -CH(OH)R6c, -CH(OR5h)R6d, -CONR6R6a, -NHCOR5c, -NHSO2R5d, -NHSO2Aryl, Aryl, -SR5e, -SOR5f, -SO2R5g, -SO2Aryl, or a five, six or seven membered heterocycle, or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle；R5, R5a, R5b, R5c, R5d, R5e, R5f, R5g, R5h and R5i are independently lower alkyl；R6, R6a, R6b, R6c and R6d are independently hydrogen, alkyl,aryl, alkylaryl or cycloalkyl, or R6 and R6a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle；A is O, S, NH, or (CH2)n where n is 0-3.A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.Derivati izoindolona, postupak za njihovu pripravu i intermedijati za taj postupak, njihova upotreba kao lijekova i farmaceutski sastavi koji ih sadrže. Predloženi izum odnosi se na nove derivate izoindolona formule (I),u kojoj R1 do R6 imaju značenja data u patentnim zahtjevima. Novi spojevi su prikladni kao antiaritmijski lijekovi s kardioprotektivnom komponentom za sprečavanje i za liječenje infarkta i za liječenje angine pektoris. Oni također preventivno inhibiraju patofiziološke procese povezane s razvojem ozljeda uzrokovanih ishemijom, posebno pojave kardijalnih aritmija uzrokovanih ishemijom i otkazivanja srca.
